Humoral immunity in renal transplantation: Clinical significance and therapeutic approach

Clinical Transplantation

Volumn 22, Issue 6, 2008, Pages 689-699

  Rowshani, Ajda T ^a,c   Bemelman, Frederieke J ^a   Lardy, Neubury M ^b   Ten Berge, Ineke J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HLA Diagnostics Laboratory   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anti CD20 monoclonal antibodies; Chronic antibody mediated rejection; Desensitization; Donor specific allo antibodies; Humoral rejection; Kidney transplantation

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ALLOANTIBODY; ANTIBODY; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SCREENING; B LYMPHOCYTE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY;

ANTIBODY FORMATION; HUMANS; KIDNEY TRANSPLANTATION;

EID: 56349142091     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00872.x     Document Type: Review

References (98)

1. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am J Transplant 2003: 3: 653.
2. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001: 344: 726.
3. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005: 16: 2804.
4. Ingelfinger JR. Agonistic autoantibodies and rejection of renal allografts. N Engl J Med 2005: 352: 617.
5. Lenaers J, Christiaans M, Van HE et al. Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting. Transplantation 2006: 81: 614.
6. Zachary AA, Klingman L, Thorne N et al. Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation 1995: 60: 498.
7. Gebel HM, Bray RA. Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 2000: 69: 1370.
8. Christiaans MH, Overhof R, Ten HA et al. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 1996: 62: 1341.
9. Claas FH, Witvliet MD, Duquesnoy RJ et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004: 78: 190.
10. de Klerk M, Witvliet MD, Haase-Kromwijk BJ et al. A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation 2006: 82: 1616.
11. de Klerk M, Keizer KM, Claas FH et al. The Dutch national living donor kidney exchange program. Am J Transplant 2005: 5: 2302.
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001: 345: 747.
13. Daeron M. Fc receptor biology. Annu Rev Immunol 1997: 15: 203.
14. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001: 291: 484.
15. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631.
16. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758.
17. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887.
18. Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000: 70: 1531.
19. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006: 6: 859.
20. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001: 357: 33.
21. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004: 77: 542.
22. Gloor JM, De Goey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003: 3: 1017.
23. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003: 76: 730.
24. Takahashi K, Saito K, Takahara S et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004: 4: 1089.
25. Segev DL, Simpkins CE, Warren DS et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005: 5: 2570.
26. Sawada T, Fuchinoue S, Kawase T et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004: 18: 254.
27. Tyden G, Kumlien G, Genberg H et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005: 5: 145.
28. Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006: 6: 346.
29. Jordan SC, Vo AA, Peng A et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006: 6: 459.
30. Dean PG, Gloor JM, Stegall MD. Conquering absolute contraindications to transplantation: Positive-crossmatch and ABO-incompatible kidney transplantation. Surgery 2005: 137: 269.
31. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 2004: 8: 535.
32. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003: 76: 1519.
33. Montgomery RA, Cooper M, Kraus E et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transplant 2003: 199.
34. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004: 4: 1315.
35. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256.
36. Tyan DB, Li VA, Czer L et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553.
37. Jordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006: 1: 421.
38. Lorenz M, Regele H, Schillinger M et al. Risk factors for capillary C4d deposition in kidney allografts: Evaluation of a large study cohort. Transplantation 2004: 78: 447.
39. Goodyear CS, Silverman GJ. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci USA 2004: 101: 11392.
40. Silverman GJ, Goodyear CS, Siegel DL. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 2005: 45: 274.
41. Rentenaar RJ, van Diepen FN, Meijer RT et al. Immune responsiveness in renal transplant recipients: Mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002: 62: 319.
42. Pescovitz MD, Book BK, Henson S et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003: 3: 497.
43. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005: 5: 39.
44. Hill P, Gagliardini E, Ruggenenti P, Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol Dial Transplant 2005: 20: 1741.
45. Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004: 78: 919.
46. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005: 5: 1569.
47. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004: 4: 438.
48. Terasaki PI, Cai J. Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005: 17: 541.
49. Varnavidou-Nicolaidou A, Iniotaki-Theodoraki AG, Doxiadis II et al. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome. Hum Immunol 2005: 66: 985.
50. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005: 365: 1570.
51. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999: 56: 783.
52. Joosten SA, Sijpkens YW, Van HV et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005: 5: 383.
53. Miettinen A, Stow JL, Mentone S, Farquhar MG. Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening. J Exp Med 1986: 163: 1064.
54. Zou Y, Stastny P, Susal C et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007: 357: 1293.
55. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004: 351: 2715.
56. Williams JM, Holzknecht ZE, Plummer TB et al. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 2004: 78: 1471.
57. King KE, Warren DS, Samaniego-Picota M et al. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004: 16: 545.
58. Ahern AT, Artruc SB, Della Pelle P et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocyte and endothelial reactive antibodies. Transplantation 1982: 33: 103.
59. Racusen LC. Antibody-mediated rejection in the kidney. Transplant Proc 2004: 36: 768.
60. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003: 3: 708.
61. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004: 4: 1033.
62. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002: 13: 779.
63. Nickeleit V, Zeiler M, Gudat F et al. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002: 13: 242.
64. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002: 13: 234.
65. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001: 12: 574.
66. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003: 18: 2232.
67. Yard B, Spruyt-Gerritse M, Claas F et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993: 55: 1287.
68. Le Bas-Bernardet S, Hourmant M, Coupel S et al. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003: 3: 167.
69. Liptak P, Kemeny E, Morvay Z et al. Peritubular capillary damage in acute humoral rejection: An ultrastructural study on human renal allografts. Am J Transplant 2005: 5: 2870.
70. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005: 352: 558.
71. Cornell LD, Colvin RB. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2005: 14: 229.
72. Ivanyi B, Fahmy H, Brown H et al. Peritubular capillaries in chronic renal allograft rejection: A quantitative ultrastructural study. Hum Pathol 2000: 31: 1129.
73. Vongwiwatana A, Gourishankar S, Campbell PM et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004: 4: 124.
74. Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001: 72: 77.
75. Cardarelli F, Pascual M, Tolkoff-Rubin N et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transplant Int 2005: 18: 532.
76. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002: 74: 1192.
77. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002: 13: 2371.
78. Piazza A, Poggi E, Borrelli L et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001: 71: 1106.
79. Pelletier RP, Hennessy PK, Adams PW et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002: 2: 134.
80. Worthington JE, Martin S, Al Husseini DM et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003: 75: 1034.
81. Pascual M, Saidman S, Tolkoff-Rubin N et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998: 66: 1460.
82. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003: 196: 197.
83. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996: 183: 699.
84. Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001: 71: 652.
85. Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003: 75: 1490.
86. White NB, Greenstein SM, Cantafio AW et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004: 78: 772.
87. Bohmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: Effective treatment by immunoadsorption. J Am Soc Nephrol 2001: 12: 2482.
88. Ibernon M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005: 37: 3743.
89. Lehrich RW, Rocha PN, Reinsmoen N et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: Experience in renal allograft transplantation. Hum Immunol 2005: 66: 350.
90. Abraham KA, Brown C, Conlon PJ et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apher 2003: 18: 103.
91. Hippen BE, De Mattos A, Cook WJ et al. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005: 5: 2248.
92. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003: 349: 125.
93. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004: 4: 996.
94. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 2006: 6: 1341.
95. Keystone E. B cell targeted therapies. Arthritis Res Ther 2005: 7(Suppl. 3): S13.
96. Pascual M, Duchosal MA, Steiger G et al. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 1993: 151: 1702.
97. Pierson RN III, Loyd JE, Goodwin A et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002: 74: 79.
98. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006: 355: 1233.